Detection and follow-up of chronic obstructive pulmonary disease (COPD) and risk factors in the Southern Cone of Latin America. the pulmonary risk in South America (PRISA) study

BMC Pulmonary Medicine

Jiang He⁶  Pamela Seron⁴  Jacqueline Ponzo¹  Héctor Olivera⁷  Jose A Manfredi²  Alison G Lee³  Fernando Lanas⁴  Matías Calandrelli⁵  Edgardo Sobrino⁸  Lydia A Bazzano⁶  Vilma E Irazola⁸  Adolfo L Rubinstein⁸ 

[1] Department of Family Medicine, Universidad de la República, Montevideo, (11000), Uruguay;Department of Cardiology, Universidad de la República, Canelones, (90000), Uruguay;Fogarty Fellow, Centro de Excelencia en Salud Cardiovascular para el Cono Sur, Instituto de Efectividad Clínica y Sanitaria, (Emilio Ravignani 2024), Buenos Aires, (C1414CPV), Argentina;Universidad de La Frontera, (Avenida Francisco Salazar 01145), Temuco, Chile;Department of Cardiology, Sanatorio San Carlos, (Mitre 124), San Carlos de Bariloche, (8400) Argentina;Department of Epidemiology School of Public Health and Tropical Medicine, Tulane University, (1440 Canal Street), New Orleans (70112), USA;Secretaría de Salud, Municipalidad de Marcos Paz, Marcos Paz, (1727), Argentina;Centro de Excelencia en Salud Cardiovascular para el Cono Sur, Instituto de Efectividad Clínica y Sanitaria, (Emilio Ravignani 2024), Buenos Aires, (C1414CPV), Argentina

关键词: Cohort;    South America;    Risk Factors;    Chronic Obstructive Pulmonary Disease;   

Others  :  1172543
DOI  :  10.1186/1471-2466-11-34

 received in 2011-05-03, accepted in 2011-06-01,  发布年份 2011

【 摘 要 】

Background

The World Health Organization has estimated that by 2030, chronic obstructive pulmonary disease will be the third leading cause of death worldwide. Most knowledge of chronic obstructive pulmonary disease is based on studies performed in Europe or North America and little is known about the prevalence, patient characteristics and change in lung function over time in patients in developing countries, such as those of Latin America. This lack of knowledge is in sharp contrast to the high levels of tobacco consumption and exposure to biomass fuels exhibited in Latin America, both major risk factors for the development of chronic obstructive pulmonary disease. Studies have also demonstrated that most Latin American physicians frequently do not follow international chronic obstructive pulmonary disease diagnostic and treatment guidelines. The PRISA Study will expand the current knowledge regarding chronic obstructive pulmonary disease and risk factors in Argentina, Chile and Uruguay to inform policy makers and health professionals on the best policies and practices to address this condition.

Methods/Design

PRISA is an observational, prospective cohort study with at least four years of follow-up. In the first year, PRISA has employed a randomized three-staged stratified cluster sampling strategy to identify 6,000 subjects from Marcos Paz and Bariloche, Argentina, Temuco, Chile, and Canelones, Uruguay. Information, such as comorbidities, socioeconomic status and tobacco and biomass exposure, will be collected and spirometry, anthropometric measurements, blood sampling and electrocardiogram will be performed. In year four, subjects will have repeat measurements taken.

Discussion

There is no longitudinal data on chronic obstructive pulmonary disease incidence and risk factors in the southern cone of Latin America, therefore this population-based prospective cohort study will fill knowledge gaps in the prevalence and incidence of chronic obstructive pulmonary disease, patient characteristics and changes in lung function over time as well as quality of life and health care resource utilization. Information gathered during the PRISA Study will inform public health interventions and prevention practices to reduce risk of COPD in the region.

【 授权许可】

   
2011 Rubinstein et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Committee G: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Medical Communications Resources, Inc; 2009.
• [2]Mary Ellen Wewers WCB, Kai-Hakin Carlsen, Mark EisnerD, Patricia Folan, Janie Heath, Mary KlinnertD, Tom Kovesi, Grace PienW, Virginia ReichartC, Arunabh Talwar, Katherine Thompson: An Official American Thoracic Society Workshop Report: Tobacco Control Initiatives within the American Thoracic Society. Proc Am Thorac Soc 2010, 7:1-7.
• [3]Organization WH: World Health Statistics 2008. 2008, 110.
• [4]Halbert RJ NJ, Gano A, Badamgarav E, Buist AS, Mannino DM: Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006, 28:523-532.
• [5]Miravitlles M, Murio C, Tirado-Conde G, Levy G, Muellerova H, Soriano JB, Ramirez-Venegas A, Ko FW, Canelos-Estrella B, Giugno E, et al.: Geographic differences in clinical characteristics and management of COPD: the EPOCA study. Int J Chron Obstruct Pulmon Dis 2008, 3:803-814.
• [6]Hnizdo GHE, Petsonk E, Buist A: Case definitions for Chronic Obstructive Pulmonary Disease. J COPD 2006, 3:1-6.
• [7]Wilt TJ ND, Kim C, Kane RL, Linabery A, Tacklind J, Macdonald R, Rutks I: Use of spirometry for case finding, diagnosis, and management of chronic obstructive pulmonary disease (COPD). Evid Rep Technol Assess (summ) 2005, 121:1-7.
• [8]Menezes AM, Perez-Padilla R, Jardim JR, Muino A, Lopez MV, Valdivia G, Montes de Oca M, Talamo C, Hallal PC, Victora CG: Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005, 366:1875-1881.
• [9]Sáenz CB SM, Blaho E, et al.: Costos en enfermedad pulmonar obstructiva crónica. Revista Argentina de Medicina Respiratoria 2001, 1:45-51.
• [10]Champagne BM, Sebrie EM, Schargrodsky H, Pramparo P, Boissonnet C, Wilson E: Tobacco smoking in seven Latin American cities: the CARMELA study. Tob Control 19:457-462.
• [11]Muller F, Wehbe L: Smoking and smoking cessation in Latin America: a review of the current situation and available treatments. Int J Chron Obstruct Pulmon Dis 2008, 3:285-293.
• [12]Taha A, Ball K: Tobacco and the Third World: the growing threat. East Afr Med J 1985, 62:735-741.
• [13]L SA: Diseño Razonado De Muestras Y Captación De Datos Para La Investigación Sanitaria. 2000.
• [14]Lemeshow LP: Sampling of Populations: Methods and Applications. 1999.
• [15]Campaign for Tobacco-fee Kids: International Resource Center [http://www.tobaccofreecenter.org] webcite
• [16]Usual Dietary Intakes: NHANES Food Frequency Questionnaire (FFQ) [http://riskfactor.cancer.gov/diet/usualintakes/ffq.html] webcite
• [17]Kroenke SRK, Williams JB: The PHQ-9: Validity of a Brief Depression Severity Measure. J Gen Intern Med 2001, 16:606-613.
• [18]S B: Screening of mental disorders in primary care: linguistic adaptation procedure of a diagnostic instrument. Acta psiquiátr psicol Am Lat 1999, 45:223-234.
• [19]The Hispanic Community Health Study/Study of Latinos [http://www.cscc.unc.edu/hchs/] webcite
• [20]International Physical Activity Questionnaire [http://www.ipaq.ki.se/ipaq.htm] webcite
• [21]The SF-12: An Even Shorter Health Survey [http://www.sf-36.org/tools/sf12.shtml] webcite
• [22]European Quality of Life 5-Dimensions [http://www.euroqol.org/] webcite
• [23]Augustovski FA IV, Velazquez AP, Gibbons L, Craig BM: Argentine valuation of the EQ-5D health states. Value Health 2009, 12:587-596.
• [24]Augustovski FA LG, Elorrio EG, Rubinstein A: The Argentine-Spanish SF-36 Health Survey was successfully validated for local outcome research. J Clin Epidemiol 2008, 61:1279-1284.
• [25]Hosmer D, Lemeshow S: Applied logistic regression. 2nd edition. 2000.
• [26]Kleinbaum D, Kupper LN, A Muller K: Applied Regression Analysis and Multivariable Methods. 3rd edition. Duxbury Applied; 2007.
• [27]Hosmer D, May S: Applied Survival Analysis: Regression Modeling of Time to Event Data. 2nd edition. 2008.
• [28]Celli BR, MacNee W: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946.
• [29]Laszlo G: Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force. Thorax 2006, 61:744-746.
• [30]Standardized lung function testing. Official statement of the European Respiratory Society Eur Respir J Suppl 1993, 16:1-100.